ERIS LIFESCIENCES LIMITED (ERIS) financials

ERIS LIFESCIENCES LIMITED (ERIS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Market Cap: ₹15,877Cr.
Current Price: ₹1,144
Stock P/E: 77.0
ROE: 8.88%
ROCE: 11.0%
Book Value: ₹231
Dividend Yield: 0.63%
52W High / Low: ₹1,740/1,131

In Jun 2026, ERIS LIFESCIENCES LIMITED (ERIS) reported sales ₹444 Cr and net profit ₹48 Cr.

Annual TTM: sales ₹1,687 Cr, net profit ₹192 Cr.

Shareholding: Promoters 54.14% (Jun 2026), FIIs 5.76% (Jun 2026), DIIs 20.71% (Jun 2026), Public 19.39% (Jun 2026), No. of Shareholders 50,798% (Jun 2026).

ERIS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	437	400	405	579	650	315	277	444
Expenses	294	300	284	362	354	238	256	324
Operating Profit	143	100	121	216	297	77	22	120
OPM %	33%	25%	30%	37%	46%	25%	8%	27%
Other Income	6	8	17	23	24	10	27	26
Interest	56	55	53	45	46	45	43	42
Depreciation	46	47	43	38	39	39	39	40
Profit before tax	46	6	41	156	235	4	-33	64
Tax %	39%	70%	26%	36%	36%	21%	-74%	25%
Net Profit	28	2	30	100	150	3	-9	48
EPS in Rs	2.06	0.13	2.24	7.34	10.98	0.23	-0.62	3.49
Raw PDF	—	—	—	—	—	—	—	—

ERIS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1,020	1,109	1,216	1,331	1,487	1,698	1,822	1,687
Expenses	661	691	727	825	1,031	1,210	1,209	1,171
Operating Profit	359	417	488	506	456	487	612	516
OPM %	35%	38%	40%	38%	31%	29%	34%	31%
Other Income	11	10	25	16	33	35	84	87
Interest	2	1	3	21	57	220	180	177
Depreciation	45	38	51	65	102	182	154	157
Profit before tax	324	389	459	437	329	120	362	270
Tax %	10%	10%	9%	9%	9%	36%	33%	—
Net Profit	291	351	417	398	300	77	244	192
EPS in Rs	21.45	25.82	30.69	29.27	22.03	5.68	17.62	14.08
Dividend Payout %	13%	21%	20%	25%	0%	129%	41%	—

ERIS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	14	14	14	14	14	14	14	14
Reserves	1,142	1,286	1,562	1,905	2,208	2,510	2,501	3,182
Borrowings	176	0	0	0	317	2,572	2,245	2,101
Other Liabilities	138	183	179	232	245	254	463	481
Total Liabilities	1,470	1,483	1,755	2,150	2,784	5,350	5,222	5,778
Fixed Assets	484	601	584	642	898	1,516	2,412	2,353
CWIP	3	4	2	3	0	1	0	0
Investments	580	320	531	778	997	1,619	991	1,414
Other Assets	403	558	638	728	889	2,214	1,819	2,011
Total Assets	1,470	1,483	1,755	2,150	2,784	5,350	5,222	5,778

ERIS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	216	265	395	369	322	336	702	564
Cash from Investing Activity	2	127	-348	-268	-513	-2,492	-359	-694
Cash from Financing Activity	-221	-334	-81	-88	194	2,160	-310	71
Net Cash Flow	-2	58	-34	13	3	4	32	-59
Free Cash Flow	180	121	370	317	11	-13	694	515
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	86%	88%	111%	93%	79%	90%	147%	104%

ERIS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	54.87%	54.86%	54.85%	54.83%	54.85%	54.85%	53.92%	54.14%
FIIs	8.01%	8.36%	8.43%	8.39%	7.21%	6.85%	6.39%	5.76%
DIIs	18.64%	18.07%	18.07%	18.18%	19.36%	20.31%	20.35%	20.71%
Public	18.47%	18.73%	18.64%	18.59%	18.57%	17.97%	19.33%	19.39%
No. of Shareholders	46,346	53,314	50,087	52,225	59,438	54,713	51,656	50,798

ERIS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	31	50	37	41	63	59	51	62
Inventory Days	206	145	119	155	98	119	140	71
Days Payable	207	200	159	177	128	143	158	128
Cash Conversion Cycle	30	-4	-3	19	33	35	33	4
Working Capital Days	-22	58	65	80	52	-413	-99	-145
ROCE %	26%	24%	27%	27%	20%	10%	7%	11%

ERISUpdated 19 Oct 2026, 5:24

Eris Lifesciences Limited

ERISUpdated 19 Oct 2026, 5:24

Market Cap

₹15,877Cr.

Current Price

₹1,144

High / Low

₹1,740/1,131

Stock P/E

77.0

ROE8.88%

ROCE11.0%

Book Value₹231

Face Value₹1.00

Dividend Yield0.63%

About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	411	7	256	4	20	133	16	111	8.14
Sep 2023	410	7	265	7	25	120	2	118	8.66
Dec 2023	324	15	250	3	28	35	9	32	2.33
Mar 2024	341	29	262	20	29	42	5	40	2.9
Jun 2024	457	56	333	5	46	27	36	17	1.25
Sep 2024	437	56	294	6	46	46	39	28	2.06
Dec 2024	400	55	300	8	47	6	70	2	0.13
Mar 2025	405	53	284	17	43	41	26	30	2.24
Jun 2025	579	45	362	23	38	156	36	100	7.34
Sep 2025	650	46	354	24	39	235	36	150	10.98
Dec 2025	315	45	238	10	39	4	21	3	0.23
Mar 2026	277	43	256	27	39	-33	-74	-9	-0.62
Jun 2026	444	42	324	26	40	64	25	48	3.49

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	548	0	437	7	15	103	19	83	5.95
Mar 2016	605	0	435	3	20	154	10	138	9.86
Mar 2017	713	1	442	25	21	274	9	248	18.05
Mar 2018	761	10	445	28	22	312	6	294	21.36
Mar 2019	897	23	562	32	32	312	8	285	20.75
Mar 2020	1020	2	661	11	45	324	10	291	21.45
Mar 2021	1109	1	691	10	38	389	10	351	25.82
Mar 2022	1216	3	727	25	51	459	9	417	30.69
Mar 2023	1331	21	825	16	65	437	9	398	29.27
Mar 2024	1487	57	1031	33	102	329	9	300	22.03
Mar 2025	1698	220	1210	35	182	120	36	77	5.68
Mar 2026	1822	180	1209	84	154	362	33	244	17.62
TTM	1687	177	1171	87	157	270	—	192	14.08

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	54.14%
FIIs	5.76%
DIIs	20.71%
Public	19.39%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	54.91%	13.2%	14.52%	17.37%
Dec 2023	54.9%	13.13%	14.55%	17.41%
Mar 2024	54.9%	14.27%	15.63%	15.2%
Jun 2024	54.88%	14.59%	16.23%	14.3%
Sep 2024	54.87%	8.01%	18.64%	18.47%
Dec 2024	54.86%	8.36%	18.07%	18.73%
Mar 2025	54.85%	8.43%	18.07%	18.64%
Jun 2025	54.83%	8.39%	18.18%	18.59%
Sep 2025	54.85%	7.21%	19.36%	18.57%
Dec 2025	54.85%	6.85%	20.31%	17.97%
Mar 2026	53.92%	6.39%	20.35%	19.33%
Jun 2026	54.14%	5.76%	20.71%	19.39%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	0.14	267	1	86	354	61	0	182	110	354
Mar 2016	0.14	305	0	96	402	65	0	206	131	402
Mar 2017	14	561	0	82	657	92	0	381	184	657
Mar 2018	14	854	376	126	1370	490	0	546	335	1370
Mar 2019	14	1142	176	138	1470	484	3	580	403	1470
Mar 2020	14	1286	0	183	1483	601	4	320	558	1483
Mar 2021	14	1562	0	179	1755	584	2	531	638	1755
Mar 2022	14	1905	0	232	2150	642	3	778	728	2150
Mar 2023	14	2208	317	245	2784	898	0	997	889	2784
Mar 2024	14	2510	2572	254	5350	1516	1	1619	2214	5350
Mar 2025	14	2501	2245	463	5222	2412	0	991	1819	5222
Mar 2026	14	3182	2101	481	5778	2353	0	1414	2011	5778

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	92	-94	1	-1
Mar 2016	133	-45	-84	4
Mar 2017	210	-199	-18	-6
Mar 2018	236	-593	363	7
Mar 2019	216	2	-221	-2
Mar 2020	265	127	-334	58
Mar 2021	395	-348	-81	-34
Mar 2022	369	-268	-88	13
Mar 2023	322	-513	194	3
Mar 2024	336	-2492	2160	4
Mar 2025	702	-359	-310	32
Mar 2026	564	-694	71	-59

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	16	15	21	29	31	50	37	41	63	59	51	62
Inventory Days	181	156	161	194	206	145	119	155	98	119	140	71
Days Payable	121	88	86	266	207	200	159	177	128	143	158	128
Cash Conversion Cycle	75	84	97	-43	30	-4	-3	19	33	35	33	4
Working Capital Days	13	8	31	2	-22	58	65	80	52	-413	-99	-145
ROCE %	44%	53%	62%	35%	26%	24%	27%	27%	20%	10%	7%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ERIS LIFESCIENCES LIMITED (ERIS)?

The reported market capitalisation for ERIS LIFESCIENCES LIMITED (ERIS) is ₹15,877Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ERIS?

The current price shown for ERIS LIFESCIENCES LIMITED (ERIS) on Fincrux is ₹1,144 with a 52-week high/low of ₹1,740/1,131.

What is the P/E ratio of ERIS LIFESCIENCES LIMITED (ERIS)?

The stock P/E for ERIS LIFESCIENCES LIMITED (ERIS) is 77.0 on Fincrux, with ROE at 8.88% and ROCE at 11.0%.

What were ERIS latest quarterly results?

For Jun 2026, ERIS LIFESCIENCES LIMITED (ERIS) reported sales ₹444 Cr and net profit ₹48 Cr (figures in ₹ crore unless noted).

What are ERIS annual sales and net profit?

For TTM, ERIS LIFESCIENCES LIMITED (ERIS) shows sales of ₹1,687 Cr and net profit of ₹192 Cr on the Fincrux profit & loss statement.

Who owns ERIS LIFESCIENCES LIMITED (ERIS)?

Latest shareholding for ERIS LIFESCIENCES LIMITED (ERIS) on Fincrux: Promoters 54.14% (Jun 2026), FIIs 5.76% (Jun 2026), DIIs 20.71% (Jun 2026), Public 19.39% (Jun 2026), No. of Shareholders 50,798% (Jun 2026).

Where can I find ERIS LIFESCIENCES LIMITED (ERIS) financials?

ERIS LIFESCIENCES LIMITED (ERIS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ERIS balance sheet and cash flow?

Yes. The ERIS LIFESCIENCES LIMITED (ERIS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:24